<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   The management of atrial fibrillation in patients with heart failure
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       The management of atrial fibrillation in patients with heart failure
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        The management of atrial fibrillation in patients with heart failure
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brian Olshansky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Wilson S Colucci, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bradley P Knight, MD, FACC
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 30, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrial fibrillation (AF) is common among patients with heart failure (HF). This topic will focus on the acute and long-term management and prognosis of AF in patients with HF, including those with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).
        </p>
        <p>
         Our recommendations are similar to those made in the 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guideline, its 2019 focused update, the 2021 guideline for AF management in HFrEF, and the joint European Heart Rhythm Association/Heart Failure Association consensus document on AF [
         <a href="#rid1">
          1-5
         </a>
         ].
        </p>
        <p>
         The general management of patients with HFrEF and HFpEF is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3461.html" rel="external">
          "Treatment and prognosis of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The management of AF in HF for patients with specific cardiomyopathies and valvular disease are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypertrophic cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/4926.html" rel="external">
          "Hypertrophic cardiomyopathy in adults: Supraventricular tachycardias including atrial fibrillation", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amyloid cardiomyopathy. (See
         <a class="medical medical_review" href="/z/d/html/85952.html" rel="external">
          "Cardiac amyloidosis: Treatment and prognosis", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Valvular heart disease. (See
         <a class="medical medical_review" href="/z/d/html/8139.html" rel="external">
          "Rheumatic mitral stenosis: Overview of management", section on 'Management of atrial fibrillation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8117.html" rel="external">
          "Medical management of asymptomatic aortic stenosis in adults", section on 'Atrial fibrillation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8149.html" rel="external">
          "Chronic primary mitral regurgitation: Indications for intervention", section on 'With normal LV function'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of AF in patients with HF varies from less than 10 to 57 percent, depending in part upon the severity of HF [
         <a href="#rid6">
          6-11
         </a>
         ]. For instance, the prevalence of AF increases from 4 to 50 percent as the New York Heart Association functional class increases from I to IV [
         <a href="#rid12">
          12-19
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3477.html" rel="external">
          "Predictors of survival in heart failure with reduced ejection fraction", section on 'NYHA functional class'
         </a>
         .)
        </p>
        <p>
         However, AF was recently associated with heart failure with reduced ejection fraction (HFrEF) and HF with preserved EF (HFpEF) events, with no significant difference in the strength of association among these subtypes, and many comorbidities (eg, anemia, renal failure, hypertension, valvular disease, coronary artery disease, etc) may also contribute to the development of AF in HF patients [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         The presence of either HF or AF increases the likelihood that the other will develop over time [
         <a href="#rid21">
          21
         </a>
         ]. The temporal associations of AF and HF were studied in over 10,000 individuals in the Framingham Heart Study [
         <a href="#rid22">
          22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 1737 persons with new AF, 37 percent had HF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 1166 persons with new HF, 57 percent had AF. Of these, 41 percent had HFpEF and 44 percent had HFrEF (15 percent could not be classified).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of both AF and HF predicted greater mortality risk compared with having neither condition, particularly among individuals with HFrEF. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         In the investigation from the Framingham Heart Study, prevalent AF was more strongly associated with incident HFpEF than HFrEF (hazard ratios [HRs] 2.34 versus 1.48) [
         <a href="#rid21">
          21
         </a>
         ]. However, a more recent study of over 25,000 participants in the REGARDS cohort did not show differential associations between AF and the development of HFpEF compared with HFrEF (HR 1.87 and 1.67 respectively, p interaction = 0.58) [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          MECHANISMS OF CARDIAC DYSFUNCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         AF can impair myocardial function by multiple mechanisms that cause or worsen HF [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1041.html" rel="external">
          "Hemodynamic consequences of atrial fibrillation and cardioversion to sinus rhythm"
         </a>
         .)
        </p>
        <p>
         Specific mechanisms include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tachycardia, bradycardia, abrupt heart rate change, and irregular rhythm may decrease cardiac output.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistent tachycardia may lead to arrhythmia-induced cardiomyopathy or can worsen a preexisting cardiomyopathy [
         <a href="#rid24">
          24-26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy", section on 'Atrial fibrillation and atrial flutter'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loss of atrial systole prevents optimal ventricular filling. Patients with diastolic HF are especially symptomatic in AF since left ventricular (LV) filling is more dependent on atrial contraction. (See
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AF can lead to maladaptive vasoconstriction from angiotensin II, norepinephrine, and other procoagulant biochemicals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The left atrial remodeling that occurs in AF can lead to atrial fibrosis, dilation and dysfunction (this is sometimes referred to as an “atriopathy”). This can cause mitral and/or tricuspid regurgitation, which exacerbate HF.
        </p>
        <p>
        </p>
        <p>
         HF is also a risk factor for AF, possibly mediated by left atrial stretch. (See
         <a class="medical medical_review" href="/z/d/html/16402.html" rel="external">
          "Mechanisms of atrial fibrillation", section on 'Triggers of AF'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2064525546">
         <span class="h1">
          GOALS OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AF and HF, we set the following goals of therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Manage acute HF exacerbation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Control symptoms; prevent cardiac dysfunction and subsequent HF and/or hemodynamic compromise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prevent arterial thromboembolism, particularly stroke
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduce mortality and cardiac hospitalization
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1839191962">
         <span class="h1">
          ACUTE DECOMPENSATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The general approach to managing acute HF decompensation with AF involves anticoagulation, treating the acute HF exacerbation, rate control to &lt;120 beats per minute, correction of reversible causes, and (only in rare instances) cardioversion. To manage acute decompensated HF with uncontrolled rates in AF, hospitalization is generally required.
        </p>
        <p>
         AF can precede an acute HF exacerbation, and uncontrolled HF can accelerate the ventricular response of AF or precipitate AF in patients in sinus rhythm.
        </p>
        <p class="headingAnchor" id="H3775265094">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients can present with sudden pulmonary congestion and an increase in the ventricular rate of AF, causing palpitations and shortness of breath and hypotension leading to dizziness or even syncope.
        </p>
        <p class="headingAnchor" id="H3794159705">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prior to or concurrent with treating the acute HF exacerbation, we
         <em>
         </em>
         anticoagulate patients with AF and HF; if the patient has acute HF symptoms, we prioritize HF treatment. Because of the high risk of thromboembolism in these patients, we anticoagulate irrespective of ejection fraction (EF), whether or not a long-term rate or rhythm control management strategy is employed, and even if patient has a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 [
         <a href="#rid27">
          27
         </a>
         ]. However, if a patient has contraindications to anticoagulation such as a high risk of bleeding, we do not anticoagulate them. (See
         <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">
          "Atrial fibrillation in adults: Selection of candidates for anticoagulation"
         </a>
         .)
        </p>
        <p>
         In addition, effective anticoagulation is required prior to, during, and after cardioversion, whether it be pharmacological or electrical. Details regarding anticoagulation and the role of transesophageal echocardiography prior to cardioversion in patients with AF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/906.html" rel="external">
          "Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1315380600">
         <span class="h2">
          Acute heart failure management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We treat HF with diuretics, vasodilators, and other measures as appropriate. This is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3450.html" rel="external">
          "Treatment of acute decompensated heart failure: Specific therapies", section on 'Initial therapy'
         </a>
         .)
        </p>
        <p>
         As part of acute HF management in patients with AF, we also slow the ventricular response.
        </p>
        <p class="headingAnchor" id="H1322234759">
         <span class="h2">
          Acute rate control
         </span>
         <span class="headingEndMark">
          —
         </span>
         We aim to reduce the ventricular rate to &lt;120 beats per minute. We do not rate control to lower ventricular rates until the acute HF exacerbation is stabilized, as patients may need a higher heart rate to maintain their cardiac output.
        </p>
        <p>
         Our specific approach to acute rate control differs for patients with HFrEF and HFpEF.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HF with reduced EF (HFrEF)
         </strong>
         – For patients with HFrEF, we use intravenous (IV)
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , IV
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , (and rarely IV
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ) to acutely control the heart rate. After starting the medication, we continually reassess the heart rate and titrate the medication to achieve the goal heart rate of &lt;120 beats per minute. Usually, we
         <em>
         </em>
         try the medication for one to two days, and if the heart rate remains elevated, we attempt another agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of medications is usually influenced by practitioner familiarity.
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         has very little negative inotropic activity and is usually more effective than
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         . However, amiodarone and IV
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         can both cause hypotension. Amiodarone is associated with conversion to sinus rhythm in a small percent of patients, which is of concern if the patient is not anticoagulated. We usually avoid diltiazem due to its negative inotropic effect that might further compromise cardiac contractility. (See
         <a class="medical medical_review" href="/z/d/html/926.html" rel="external">
          "Amiodarone: Clinical uses"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         dosing for AF rate control in all patients and among critically ill patients is presented separately. Dosing is similar for AF in patients with HF. (See
         <a class="medical medical_review" href="/z/d/html/926.html" rel="external">
          "Amiodarone: Clinical uses", section on 'Ventricular rate control in critically ill patients with atrial fibrillation and rapid ventricular response'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         dosing for AF rate control usually includes IV loading followed by a maintenance oral dose. Oral loading is also possible. (See
         <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">
          "Treatment with digoxin: Initial dosing, monitoring, and dose modification", section on 'Rapid digoxin loading'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         dosing in the acute setting is discussed separately.
        </p>
        <p>
        </p>
        <p>
         We generally avoid beta blocker therapy in patients with AF and acute decompensated HF. In such patients, the negative inotropic properties of a beta blocker may worsen the clinical condition. The use of beta blockers for long-term control of heart rate in AF is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy", section on 'Urgent therapy'
         </a>
         and
         <a class="local">
          'Rate control in heart failure with reduced ejection fraction'
         </a>
         below and
         <a class="local">
          'Rate control in heart failure with preserved ejection fraction'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HF with preserved EF
         </strong>
         (
         <strong>
          HFpEF)
         </strong>
         – In HFpEF patients who present with congestion or hypotension, rate control can be attempted first with IV
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         (which may be better tolerated in patients with borderline hypotension) or IV beta blockade. We consider these agents to be equally effective at rate control of AF in patients with HFpEF. With both medications, hypotension is a potential side effect.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          Diltiazem
         </a>
         dosing in the acute setting is discussed separately.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For the acute control of ventricular rate, IV beta blockade with
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9420" href="/z/d/drug information/9420.html" rel="external">
          esmolol
         </a>
         can be effective. Specific dosing information for these medications is presented separately. Specific dosing information is discussed separately.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1849594504">
         <span class="h2">
          Correction of reversible causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some patients, there is a reversible cause of AF, HF, or both. These are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/3457.html" rel="external">
          "Pathophysiology of heart failure with preserved ejection fraction", section on 'Decompensated HFpEF'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121085.html" rel="external">
          "Overview of the management of heart failure with reduced ejection fraction in adults", section on 'Management of causes and associated conditions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">
          "Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Triggers'
         </a>
         .)
        </p>
        <p>
         Etiologies that are specific to AF and HF include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient with existing AF develops new HF, a possible diagnosis to consider is arrythmia-induced cardiomyopathy from inadequate rate control. (See
         <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">
          "Arrhythmia-induced cardiomyopathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If a patient develops new-onset AF and HF concurrently, thyrotoxicosis should be considered as a diagnostic possibility. (See
         <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">
          "Cardiovascular effects of hyperthyroidism", section on 'Heart failure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">
          "Cardiovascular effects of hyperthyroidism", section on 'Atrial fibrillation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3531896140">
         <span class="h2">
          Role of cardioversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         We rarely consider an initial cardioversion for treatment of patients with acute decompensated HF; there is a low probability of successful or durable cardioversion unless the HF decompensation is first corrected.
        </p>
        <p>
         However, cardioversion (generally electrical) may be helpful in the following circumstances:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial attempts to decrease pulmonary congestion with diuretics, vasodilators, and rate control have failed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AF is thought to be the cause of acute HF decompensation, ie, the onset of AF has recently preceded the HF exacerbation. In such patients, even if the rate is well controlled, cardioversion may be helpful in managing HF.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with persistent evidence of myocardial ischemia. This scenario assumes that the patient does not require urgent reperfusion or other stabilizing therapies for acute coronary syndrome. (See
         <a class="medical medical_review" href="/z/d/html/66.html" rel="external">
          "Overview of the acute management of ST-elevation myocardial infarction", section on 'Choosing and initiating reperfusion with PCI or fibrinolysis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/68.html" rel="external">
          "Overview of the acute management of non-ST-elevation acute coronary syndromes", section on 'Choosing a revascularization strategy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         In patients with HFpEF, it can be difficult to tell if the HF is predominantly due to AF or some other cause.
        </p>
        <p>
         An important potential harm of cardioversion in this setting is the risk of a thromboembolic event in nonanticoagulated patients. We almost always avoid cardioversion (even in patients with hemodynamic instability or cardiogenic shock) if the patient is not adequately anticoagulated (ie, has not been on therapeutic, uninterrupted, chronic anticoagulation for at least one month prior). For patients in whom urgent cardioversion is being considered despite inadequate anticoagulation, a transesophageal echocardiogram should be considered to evaluate for a left atrial or left atrial appendage thrombus. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/908.html" rel="external">
          "Role of echocardiography in atrial fibrillation", section on 'Transesophageal echocardiography'
         </a>
         .)
        </p>
        <p>
         We avoid cardioversion in patients with long-standing persistent or permanent AF, who have failed cardioversion, or who have had early recurrence of AF after cardioversion with additional antiarrhythmic therapy.
        </p>
        <p class="headingAnchor" id="H3036521159">
         <span class="h1">
          LONG-TERM MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1074965487">
         <span class="h2">
          Long-term anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We continue anticoagulation that was started during acute management, transitioning to oral anticoagulation as appropriate. If anticoagulation was not started during the acute management phase, and if there are no contraindications, we start anticoagulation. Because of the high risk of thromboembolism in these patients, we anticoagulate irrespective of ejection fraction (EF), whether or not a long-term rate or rhythm control management strategy is employed, and even if a patient has a CHA
         <sub>
          2
         </sub>
         DS
         <sub>
          2
         </sub>
         -VASc score of 1 [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         .)
        </p>
        <p>
         Novel oral anticoagulants, instead of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , are often used for effective anticoagulation. There is increased risk of bleeding when these anticoagulants are used concomitantly with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         or other medications [
         <a href="#rid28">
          28-31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1532609463">
         <span class="h2">
          Preference for rhythm over rate control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the first management approach in acute decompensated AF with HF is often rate control, rhythm control is our preferred long-term management strategy for most patients. This includes patients with recent-onset AF, persistent HF even when rate controlled, or inadequate rate control. (See
         <a class="local">
          'Acute decompensation'
         </a>
         above.)
        </p>
        <p>
         Potential exceptions to this approach are noted below. (See
         <a class="local">
          'Exceptions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1231432707">
         <span class="h3">
          Evidence for cardiovascular benefit
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific reasons for returning the patient to sinus rhythm are to establish a symptom-rhythm correlation; this helps to establish if AF is a specific trigger or contributing factor for a patient's HF symptoms and/or worsening HF. A return to sinus rhythm can also improve cardiac function, increase exercise tolerance, and alleviate HF symptoms.
        </p>
        <p>
         Some evidence suggests that early rhythm control (ie, within one year) is beneficial for improved five-year cardiovascular outcomes in patients with HF (either HF with preserved EF [HFpEF] or reduced EF [HFrEF]). In a prespecified subanalysis of the EAST-AFNET 4 randomized trial, over 750 patients with symptomatic HF were randomly assigned to early rhythm control or usual care (which included rhythm control for symptoms) [
         <a href="#rid32">
          32
         </a>
         ]. The following was observed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The composite outcome of cardiovascular death, stroke, or hospitalization for HF or acute coronary syndrome occurred less often in patients in the early rhythm control versus usual care group (5.7 versus 7.9 per 100 patient-years; hazard ratio [HR] 0.74, 95% CI 0.56-0.97). Kaplan-Meier curves showed that event rates in the two treatment groups began to separate at six months. The two treatment groups had similar rates of all-cause mortality (9.9 versus 11.8 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Left ventricular EF (LVEF) improved in both groups (approximately 5 percent increase).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The primary safety outcome (death, stroke, or serious adverse events related to rhythm control therapy) was similar between treatment groups (17.9 versus 21.6 percent, HR 0.85, 95% CI 0.62-1.17).
        </p>
        <p>
        </p>
        <p>
         Some limitations of EAST-AFNET 4 should be mentioned. The usual care assigned to the control group in EAST-AFNET 4 may not be generalizable, as it may not reflect standard treatment of AF in patients with HF. Also, patients assigned to rhythm control received a variety of therapies; only 19 percent received catheter ablation (CA).
        </p>
        <p>
         In the subsequent RAFT-AF trial, results were similar, although the trial was stopped early for futility and did not have statistically significant findings. Four hundred and eleven patients with HF and a high burden of AF were randomly assigned to either CA-based rhythm control or rate control and followed for mortality and HF events [
         <a href="#rid33">
          33
         </a>
         ]. Patients assigned to rhythm control had a lower mortality and HF events compared with the rate control group, but the results were not statistically significant (23.4 versus 32.5 percent; HR 0.71, 95% CI 0.49-1.03). Patients in the rhythm control group also had greater improvements in LVEF (increase of 10 versus 4 percent), six-minute walk test, and HF- and AF-related quality of life. The CA-related adverse event rate was high at 11 percent. An additional limitation of this study was the lack of statistical power to detect a potential protective effect of therapy; the study was unable to recruit the anticipated number of participants due to restrictions on clinical research during the COVID-19 pandemic.
        </p>
        <p>
         Four small randomized trials, each with methodological limitations, and one observational study have compared CA with rate control in patients with HF and also found benefit [
         <a href="#rid34">
          34-38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/949.html" rel="external">
          "Atrial fibrillation: Catheter ablation", section on 'Efficacy'
         </a>
         and
         <a class="local">
          'Catheter ablation'
         </a>
         below.)
        </p>
        <p>
         A previous trial (AF-CHF) did not find a significant benefit for long-term pharmacologic rhythm control compared with rate control in patients with HFrEF and AF [
         <a href="#rid39">
          39,40
         </a>
         ]. It is important to recognize that CA was not a strategy tested in the AF-CHF trial, whereas 19 percent of patients in the rhythm control arm had CA in the EAST-AFNET 4 trial. Furthermore, in AF-CHF, the patients all had severe LV systolic dysfunction. These key differences may underline why the results in AF-CHF were null in contrast to the EAST-AFNET 4 trial described above, in which early rhythm control was beneficial.
        </p>
        <p class="headingAnchor" id="H3250517391">
         <span class="h3">
          Exceptions
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rate control strategy may be preferred in patients with longstanding AF or severe left atrial enlargement. In these cases, the cardioversion is much less likely to be successful or durable. Also, for patients with severe valvular disease (such as severe mitral regurgitation), cardioversion is less likely to be successful in maintaining sinus rhythm and reducing symptoms.
        </p>
        <p>
         A rate control strategy may also be reasonable in an older patient who is unwilling to undergo the burdens of a rhythm control strategy, particularly if they tolerate AF well. Some patients will not want to be placed on antiarrhythmic medications or undergo invasive procedures. In these patients, a rate control strategy may be pursued. If a patient has a contraindication to anticoagulation, a rate control strategy may also be preferred.
        </p>
        <p class="headingAnchor" id="H365854415">
         <span class="h2">
          Heart failure with reduced ejection fraction
         </span>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Rhythm control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Conversion to and maintenance of sinus rhythm can be achieved with electrical cardioversion, antiarrhythmic drug therapy, CA, or surgical ablation [
         <a href="#rid21">
          21
         </a>
         ]. Generally, we approach attempts at rhythm control in a step-wise fashion as outlined in the sections that follow. (See
         <a class="local">
          'Preference for rhythm over rate control'
         </a>
         above.)
        </p>
        <p>
         Rhythm control is less effective in patients with persistent AF (which is common among patients with HF) or with severe left atrial enlargement (a marker of AF chronicity).
        </p>
        <p class="headingAnchor" id="H3541386737">
         <span class="h4">
          Electrical cardioversion
         </span>
         <span class="headingEndMark">
          —
         </span>
         For nearly all patients, we first try electrical cardioversion (this can be done in conjunction with antiarrhythmic medication, which can increase the likelihood of maintaining sinus rhythm, or it can be performed without such a medication). We generally perform the initial electrical cardioversion without an antiarrhythmic medication if this is the first episode of AF, if AF is well tolerated, if HF is not difficult to manage, and if there is no hemodynamically significant mitral regurgitation or left atrial enlargement. Patients require appropriate anticoagulation prior to, during, and after cardioversion. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
         Electrical cardioversion is not appropriate in those who have short episodes of paroxysmal AF and for those in whom HF exacerbation is unlikely to be due to the AF. However, we use cardioversion if paroxysmal AF episodes last days, if there is precipitous change in condition, and if patients do not respond to an antiarrhythmic drug.
        </p>
        <p>
         After initial cardioversion, the majority of patients will have recurrent AF unless it was due to an acute precipitant that is no longer present (eg, acute pulmonary edema, myocardial infarction, pulmonary embolus, cardiac surgery). If a patient reverts to AF after cardioversion, we may try another cardioversion, this time with an antiarrhythmic medication (initiated prior to cardioversion) in order to help the patient maintain sinus rhythm.
        </p>
        <p>
         In some patients, we attempt cardioversion multiple times. Considerations include the likelihood of maintaining sinus rhythm, the time course of AF recurrence, patient symptom burden, and need for improvement of patient hemodynamics. We also try to balance these with the patient's overall preference to be in sinus rhythm. For example, if AF seems to be related to acute HF decompensation or other adverse event, repeat cardioversions are appropriate. If repeat cardioversions are not successful, we may use antiarrhythmic drugs and/or CA to maintain sinus rhythm.
        </p>
        <p class="headingAnchor" id="H2544081747">
         <span class="h4">
          Antiarrhythmic drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         In nearly all patients with HFrEF who have recurrent AF after cardioversion, we use an antiarrhythmic drug to help maintain sinus rhythm or to facilitate cardioversion if the cardioversion is not successful in achieving sinus rhythm. We always ensure the patient is appropriately anticoagulated. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
         We use
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , or
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         as the initial antiarrhythmic medication in patients with persistent AF and HF. Some experts prefer to try dofetilide first, especially in patients who are younger and have preserved kidney dysfunction. Other experts prefer to use amiodarone, given its ease of use.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         is more likely to cause the potentially life-threatening ventricular arrhythmia "torsades de pointes" in patients with HF with severe systolic dysfunction than
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         and in those with acute decompensation. Therefore, dofetilide is safer to use in patients with HF and milder systolic dysfunction, as well as those patients who have an implantable cardiac defibrillator, as these devices can prevent sudden cardiac arrest from ventricular arrhythmia. Prior to using dofetilide, during its initiation, and subsequent to initiation, measurements of QT intervals are necessary. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide", section on 'Safety'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         can worsen HF in those with HFrEF due to the beta-blocking effects and is not recommended for patients with markedly impaired LV function and acute decompensated HF. Sotalol can cause the potentially life-threatening arrythmia torsade de pointes, and thus prior to using the drug and after it is initiated, measurements of QT intervals are necessary. If the baseline QTc is greater than 450 msec, sotalol is contraindicated. Other details regarding sotalol initiation and QTc monitoring are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol", section on 'Dosing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol", section on 'Proarrhythmia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         We avoid
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         , and
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         because of worse outcomes in HFrEF patients.
        </p>
        <p>
         The following provides evidence for the efficacy of specific pharmacotherapy in AF and HF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          Dofetilide
         </a>
         – Dofetilide, a class III antiarrhythmic drug, can be effective and safe for preventing recurrent persistent AF in patients with HF. It may also be used to convert patients to sinus rhythm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recommended dose of
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         is 500 micrograms twice daily in the absence of renal insufficiency, but it is adjusted based on renal function. Patients need to be hospitalized for dofetilide initiation. Further information regarding the initiation protocol and safety of dofetilide is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the DIAMOND-CHF trial, 390 patients with AF and symptomatic HF were randomly assigned to
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         or placebo [
         <a href="#rid41">
          41
         </a>
         ]. Dofetilide was more likely to be associated with conversion to sinus rhythm at one month (12 versus 1 percent) and maintenance of sinus rhythm at one year (44 versus 13 percent; HR 0.35, 95% CI 0.22-0.57). Mortality did not differ between treatment groups (41 versus 42 percent; HR 0.95, 95% CI 0.81-1.11). In a separate investigation, among 500 patients with HFrEF and AF in the DIAMOND-HF and DIAMOND-MI studies, dofetilide was more likely than placebo to lead to conversion to sinus rhythm (59 versus 34 percent) and to maintain sinus rhythm at one year (79 versus 42 percent; relative risk 0.30, 95% CI 0.19-0.48) [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1033.html" rel="external">
          "Clinical use of dofetilide"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The most important side effect of
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         was torsades de pointes, which was seen in 25 cases (3.3 percent); three-quarters of episodes occurred within the first three days while the patient was in the hospital [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes", section on 'Definitions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         – When used for preventing recurrence of AF, advantages of low-dose amiodarone include no negative inotropic effect and little or no proarrhythmia. Advantages of amiodarone compared with
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         include the ability to start therapy as an outpatient (for AF), once-a-day dosing, and a lower risk of torsades de pointes. In addition, since amiodarone has non-competitive beta-blocking and calcium channel antagonist activity, the ventricular rate is usually slow and well tolerated if AF does recur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The recommended dose of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         is 400 mg/day. Occasionally, less than 200 mg/day is used (eg, for patients at high risk of side effects or toxicities). (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Its use in HF patients does not necessarily require hospitalization, but careful monitoring of the prothrombin time international normalized ratio is necessary, as
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         can potentiate the effects of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Adverse drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         in AF and HF was illustrated in a subset analysis from the CHF-STAT trial of over 660 patients in which 15 percent of patients had AF at baseline [
         <a href="#rid43">
          43
         </a>
         ]. Among these 103 patients, 51 were randomly assigned to amiodarone and 52 to placebo. Patients assigned to amiodarone had a higher likelihood of converting to sinus rhythm (31 versus 8 percent). Patients who converted to sinus rhythm with amiodarone had a lower mortality than those who did not. However, it is not clear if reductions in mortality were because patients who converted were less sick to begin with or if restoration of sinus rhythm was causative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Complications associated with
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         loading and long-term therapy in patients with HFrEF and AF include bradycardia requiring permanent pacemaker, hypothyroidism, and neurotoxicity [
         <a href="#rid44">
          44
         </a>
         ]. Side effects with maintenance therapy are less likely with lower doses but still occur.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         – Sotalol
         <strong>
         </strong>
         should be used with caution in patients with HF who have poor LV function (LVEF &lt;30 percent) based on increased risk for torsades de pointes [
         <a href="#rid45">
          45
         </a>
         ]. This is especially true if there are marked fluctuations in electrolyte levels, acute or decompensated HF, or renal dysfunction. (See
         <a class="medical medical_review" href="/z/d/html/3499.html" rel="external">
          "Drugs that should be avoided or used with caution in patients with heart failure", section on 'Antiarrhythmic agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/925.html" rel="external">
          "Clinical uses of sotalol", section on 'Heart failure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          Sotalol
         </a>
         can be used if the QT is not prolonged, if there is no renal dysfunction, if there are normal electrolytes (specifically normal potassium), if there is no acute decompensation, and if the LVEF is no more than modestly impaired (ie, if LVEF is &gt;30 percent). However, sotalol can cause marked bradycardia and worsen HF in HFrEF in some instances.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta blockers
         </strong>
         – Chronic beta blocker therapy may reduce the likelihood of development of AF in patients with HF due to systolic dysfunction. Likewise, in people with paroxysmal AF, beta blockers may help maintain sinus rhythm. Using beta blockers as antiarrhythmic therapy can serve a dual purpose because these medications are also an important component of optimal medical therapy for HF. (See
         <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Beta blockers'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Medications we do not suggest using in AF and HF patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          Dronedarone
         </a>
         – In general, dronedarone has no role in the management of AF in a HF patient. In particular, dronedarone should not be used in patients with New York Heart Association class III to IV HF or LV systolic dysfunction (LVEF &lt;0.40), as efficacy is low, and safety is a concern. It should also not be used in patients with longstanding persistent AF. This recommendation is consistent with that made by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fnews%2Feuropean-medicines-agency-recommends-restricting-use-multaq&amp;token=wFWKrFI1LQRMf7woG1%2BHfA8UaDTk0IHzIhJ%2BBZNO48SMqeABzh1484Rj%2B4x16qonWoZDcpVN0zqz3hnEyzrM6Az696XeZ0UpHX%2F%2FH0i%2BaLedU%2FVurREefmqwPM7KGXWH&amp;TOPIC_ID=977" target="_blank">
          European Medicines Agency in September of 2011
         </a>
         and the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-safety-and-availability%2Ffda-drug-safety-communication-review-update-multaq-dronedarone-and-increased-risk-death-and-serious&amp;token=2P5XYlVtR1ADmVZf1quCEt1eW2nZdFbi%2FZ7NWjGIvFRWK03FvmNczY7GXJ7ad4Z%2BeGP0oabiIst3%2BUsmqJN4HO%2BJWEBMNj5JC2DwCoVxnnvJvk%2BmcyjYJ9mm2Xk3pJazebFmpKLa1wx%2FvmAy0tBXnkAjhyb%2BzG%2F8o34vWMbh%2Fo0%3D&amp;TOPIC_ID=977" target="_blank">
          U S Food and Drug Administration in December of 2011
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Strong evidence for an adverse effect of
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         use in patients with HFrEF comes from the ANDROMEDA trial (patients in this study had an LVEF ≤35 percent) [
         <a href="#rid46">
          46
         </a>
         ] . The trial was discontinued early due to a significant increase in the incidence of death in the patients assigned to dronedarone versus placebo (8.1 versus 3.8 percent; HR 2.13, 95% CI 1.07-4.25). The primary cause of death among patients receiving dronedarone was worsening HF [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          Dronedarone
         </a>
         is likely less efficacious than
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         at AF rhythm control [
         <a href="#rid47">
          47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1038.html" rel="external">
          "Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials", section on 'Dronedarone'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Class IC drugs
         </strong>
         – Class IC drugs (
         <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">
          flecainide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">
          propafenone
         </a>
         ) are associated with an increased risk for proarrhythmia and sudden cardiac death and should not be used in patients with AF and HF  (
         <a class="graphic graphic_table graphicRef120433" href="/z/d/graphic/120433.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">
          Ibutilide
         </a>
         – We do not use this medication in decompensated HF due to the substantial risks of torsades de pointes. (See
         <a class="medical medical_review" href="/z/d/html/924.html" rel="external">
          "Therapeutic use of ibutilide", section on 'Proarrhythmia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1254493">
         <span class="h4">
          Catheter ablation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with symptomatic AF who have HFrEF that is not decompensated and recurrent AF despite electrical cardioversion and antiarrhythmic drug therapy (or side effect or intolerance to antiarrhythmic therapy), we perform CA of AF rather than continued attempts at cardioversion with or without antiarrhythmic drug therapy. In some patients, repeat CA is pursued if the first CA is unsuccessful. (See
         <a class="medical medical_review" href="/z/d/html/93920.html" rel="external">
          "Maintenance of sinus rhythm in atrial fibrillation: Catheter ablation versus antiarrhythmic drug therapy"
         </a>
         .)
        </p>
        <p>
         Rarely, if a patient has a contraindication to all antiarrhythmic medications and there is new AF and/or paroxysmal AF, we will pursue CA as the initial therapy. An example is a patient with HF and AF who has a contraindication to
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         (eg, kidney disease, a long QT interval) and propensity to develop
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         toxicity (eg, underlying thyroid, lung, or liver disease).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients HFrEF and AF who are unlikely to benefit from CA
         </strong>
         – If the patient has one or more of the following factors, they may be unsuitable for CA:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some patients with advanced HF (including those with LV assist device destination therapy or on ionotropic support).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Severe comorbidities or medical instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients asymptomatic on optimal HF therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Longstanding AF that is unrelated to progressive symptoms or concerns.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Older-aged persons including those with frailty. We do not generally perform CA in persons &gt;age 80 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Markedly enlarged left atrial size and longstanding persistent and drug-resistant AF. There is no evidence that suggests a specific left atrial dimension cut point beyond which CA may not be useful.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with complete heart block (either spontaneous or related to an atrioventricular node ablation) and permanent ventricular pacing.
        </p>
        <p>
        </p>
        <p>
         If the patient is deemed unsuitable for CA for one or more of these reasons and has failed other attempts at rhythm control, we pursue a rate control strategy. (See
         <a class="local">
          'Rate control in heart failure with reduced ejection fraction'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of CA versus medical therapy
         </strong>
         – The CASTLE-AF trial randomly assigned 363 patients with implantable cardioverter-defibrillators, symptomatic paroxysmal or persistent AF, New York Heart Association class II or higher, and an LVEF ≤35 percent to CA or medical therapy [
         <a href="#rid48">
          48
         </a>
         ]. Death from any cause or hospitalization for HF occurred in fewer patients in the CA compared with medical therapy group (29 versus 45 percent; HR 0.62; 95% CI 0.43-0.87). The time in AF was also lower with CA versus medical therapy (25 versus 60 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several important limitations of the CASTLE-AF trial include patients lost to follow-up (particularly in the group assigned implantable cardioverter-defibrillator), lack of blinding, small sample size, and limited generalizability given that 85 percent of participants were male (females have less successful CAs) and that all patients had defibrillators and/or cardiac resynchronization therapy. A greater number of patients in the ablation group than in the medical therapy group crossed over to the other treatment group (15.6 versus 9.8). Finally, although medical therapy (for both AF and HF) was managed per study protocol, it is possible that a nontraditional or more aggressive approach to medical management might have influenced the trial results.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a 2019 meta-analysis of six trials (775 patients), of which CASTLE-AF was the largest [
         <a href="#rid49">
          49
         </a>
         ], CA reduced all-cause mortality compared with drug therapy (9 versus 18 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Studies have also shown that CA can increase exercise ability, LVEF, quality of life, and is associated with a decrease in pro-brain natriuretic peptide levels [
         <a href="#rid34">
          34,36,37,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy of CA versus atrioventricular node ablation with biventricular pacing
         </strong>
         – In a randomized trial of 81 patients with HF and symptomatic, drug-refractory AF, CA was associated with modest improvements in LVEF (35 versus 28 percent), six-minute walk distance (340 versus 297 meters), and score on the Minnesota Living With Heart Failure questionnaire [
         <a href="#rid35">
          35
         </a>
         ]. The role of atrioventricular ablation and biventricular pacing in patients with AF is discussed in detail elsewhere. (See
         <a class="local">
          'Atrioventricular node ablation with pacing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3515.html" rel="external">
          "Cardiac resynchronization therapy in atrial fibrillation", section on 'Cardiac resynchronization therapy outcomes in patients with atrial fibrillation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H365855113">
         <span class="h3">
          Rate control in heart failure with reduced ejection fraction
         </span>
        </p>
        <p class="headingAnchor" id="H1949969842">
         <span class="h4">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         We pursue a rate control strategy for patients in whom rhythm control is not tolerated or has been unsuccessful. A rate control strategy is sometimes the preferred initial strategy in a subset of patients as outlined above. (See
         <a class="local">
          'Exceptions'
         </a>
         above.)
        </p>
        <p>
         Among patients with HF, rate control to prevent rapid AF usually leads to an improvement in symptoms. Slowing of the ventricular rate often leads to a moderate or even marked improvement in LV function [
         <a href="#rid9">
          9,25,26
         </a>
         ]. (See
         <a class="local">
          'mechanisms of cardiac dysfunction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3309579719">
         <span class="h4">
          Rate control goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         The broad goal of rate control is to minimize symptoms with exercise and rest. Thus, the adequacy of rate control should be assessed in both circumstances [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
         The optimal heart rate in patients with AF and HF has not been well studied and is not certain. Our authors generally start with a heart rate goal of &lt;85 beats per minute at rest and &lt;110 beats per minute during moderate exercise (the strict approach). If this is not possible, the goal becomes &lt;110 beats per minute at rest (the lenient approach).
        </p>
        <p>
         In a symptomatic patient in whom the ventricular rate varies markedly with minimal changes in activity, a rhythm control strategy may be necessary.
        </p>
        <p class="headingAnchor" id="H1919444248">
         <span class="h4">
          Medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although we prefer to use just one rate-slowing medication, sometimes more than one medication is required to achieve adequate heart rate control. When titrating therapy, we measure the patient's ventricular rates at rest and with moderate exertion. (See
         <a class="local">
          'Rate control goal'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Beta blocker
         </strong>
         – We usually select a beta blocker as first therapy due to their superior safety profile in both AF and HF. We would avoid starting a beta blocker if the patient had decompensated HF. Most patients with preexisting HFrEF are already on a beta blocker for treatment of HF, and if possible, we increase the dosage of their medication. The alternatives of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         (lesser efficacy) and
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         (more side effects) have significant limitations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We start with
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          carvedilol
         </a>
         , extended-release
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          metoprolol
         </a>
         succinate, or
         <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">
          bisoprolol
         </a>
         . The doses should be optimized before considering a second agent. These drugs are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/121086.html" rel="external">
          "Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Evidence'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy", section on 'Elective and long-term management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9208" href="/z/d/drug information/9208.html" rel="external">
          Carvedilol
         </a>
         is started at an oral dose of 3.125 mg twice daily. The usual dosage range is 3.125 to 25 mg twice daily but may be titrated higher for the purpose of treating HFrEF (up to 25 to 50 mg, depending on the patient's weight). A possible adverse effect of carvedilol is hypotension since this beta blocker also has alpha-adrenergic-receptor-blocking action [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">
          Metoprolol
         </a>
         succinate is started at an oral dose of 25 mg daily. This can be titrated up to a target dose of 200 mg daily in patients with HFrEF. Even if AF rate control is achieved at lower doses, the target for metoprolol succinate is higher for HFrEF.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">
          Bisoprolol
         </a>
         is started at an oral dose of 2.5 mg once daily; the dose is increased gradually as tolerated to achieve ventricular rate control, and in patients with HFrEF, the target dose is 10 mg daily.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Beta blockers have been shown to improve symptoms but not survival in AF and HF. In a meta-analysis of AF patients in 11 randomized trials of over 3000 patients, beta blockers reduced the ventricular rate (by 12 beats per minute) but did not decrease mortality when compared with placebo (overall death rate 20 percent; HR 0.96, 95% CI 0.81-1.12) [
         <a href="#rid52">
          52
         </a>
         ]. This finding was consistent with a prior study [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          Digoxin
         </a>
         <strong>
         </strong>
         – In patients who cannot receive a beta blocker or are not adequately rate controlled despite their maximal-tolerated dose, and in whom rhythm control will not be attempted, digoxin may be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This may be relevant for patients with decompensated HF, in whom initiation or increase of beta blockers is contraindicated. If such a patient also has rapid AF requiring rate control, use of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         is suggested. However, digoxin is often ineffective when used alone.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If two drugs are needed to control for long-term rate, we suggest adding
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         to a beta blocker.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing and administration of
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         are described separately. (See
         <a class="medical medical_review" href="/z/d/html/1051.html" rel="external">
          "Treatment with digoxin: Initial dosing, monitoring, and dose modification"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/938.html" rel="external">
          "Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         – In the event of inadequate rate control with beta blockers and/or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , amiodarone can be used either alone or in combination with other rate control medications. We do not generally use amiodarone as a long-term rate control medication, but in the acute setting, it can assist with rate control as it is being loaded or can be used as a temporary rate control agent in patients who are unable to tolerate other therapies [
         <a href="#rid43">
          43
         </a>
         ]. We exercise care when using amiodarone, especially in those without adequate anticoagulation since there is the possibility of pharmacologically restoring sinus rhythm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usual maintenance dose of
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         from AF is 100 to 200 mg daily after a loading dose.
        </p>
        <p>
        </p>
        <p>
         Therapies that should be avoided for AF rate control and HFrEF include
         <a class="drug drug_general" data-topicid="9037" href="/z/d/drug information/9037.html" rel="external">
          dronedarone
         </a>
         , class IC drugs, and nondihydropyridine calcium channel blockers (
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3455.html" rel="external">
          "Calcium channel blockers in heart failure with reduced ejection fraction"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3499.html" rel="external">
          "Drugs that should be avoided or used with caution in patients with heart failure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H506251413">
         <span class="h4">
          Atrioventricular node ablation with pacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rate control can also be achieved with radiofrequency ablation of the atrioventricular node and permanent pacemaker placement. This strategy may be useful in patients in whom rate control with antiarrhythmic drug or CA has failed or is contraindicated. Atrioventricular node ablation with pacing can be particularly helpful for patients with permanent AF. (See
         <a class="medical medical_review" href="/z/d/html/1012.html" rel="external">
          "Atrial fibrillation: Atrioventricular node ablation"
         </a>
         .)
        </p>
        <p>
         If the LVEF is 45 percent or less and there is an expectation that ventricular pacing will occur more than 25 percent of the time, a biventricular, His bundle, or left bundle pacing system (also called cardiac resynchronization therapy) should be considered instead of a standard right ventricular pacing system. (See
         <a class="medical medical_review" href="/z/d/html/1012.html" rel="external">
          "Atrial fibrillation: Atrioventricular node ablation", section on 'Cardiac resynchronization therapy'
         </a>
         .)
        </p>
        <p>
         In addition, atrioventricular node ablation may be necessary for some patients with HF and AF who are referred for cardiac resynchronization therapy for treatment of HF. This is because intact atrioventricular conduction may "override" pace and thus reduce efficacy of the cardiac resynchronization therapy device. In particular, atrioventricular node ablation may be beneficial for patients who are not pacing at least 90 percent with cardiac resynchronization therapy [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3515.html" rel="external">
          "Cardiac resynchronization therapy in atrial fibrillation", section on 'Role of atrioventricular node ablation in patients with heart failure and atrial fibrillation'
         </a>
         .)
        </p>
        <p>
         Left bundle or His bundle pacing have also become options, although randomized controlled clinical trials have yet to definitively demonstrate an advantage of this approach versus a cardiac resynchronization therapy approach.
        </p>
        <p class="headingAnchor" id="H365854729">
         <span class="h2">
          Heart failure with preserved ejection fraction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our long-term management approach to patients with AF and HFpEF is similar to that of patients with AF and HFrEF. The main differences are with respect to the choice of specific rhythm and rate control medications.
        </p>
        <p class="headingAnchor" id="H2932068055">
         <span class="h3">
          Rhythm control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rhythm control is the preferred long-term strategy for most patients. (See
         <a class="local">
          'Evidence for cardiovascular benefit'
         </a>
         above.)
        </p>
        <p>
         Antiarrhythmic therapy and CA approaches are similar in HFpEF and HFrEF. Some medication such as
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         tend to have fewer complications in patients with preserved LVEF (See
         <a class="local">
          'Rhythm control'
         </a>
         above.)
        </p>
        <p>
         The efficacy and safety of CA
         <strong>
         </strong>
         have been evaluated in patients with diastolic HF. A meta-analysis of 12 retrospective cohort studies confirmed the safety of CA for patients with HFpEF; over a one- to three-year follow up, complications occurred in &lt;1 percent of patients [
         <a href="#rid55">
          55
         </a>
         ]. Fifty-eight percent of patients maintained sinus rhythm without using an antiarrhythmic medication. Admission for HF and all-cause mortality each occurred in 6 percent of patients.
        </p>
        <p class="headingAnchor" id="H1872802515">
         <span class="h3">
          Rate control in heart failure with preserved ejection fraction
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with AF and HFpEF, we attempt to maintain a resting heart rate of 80 bpm or less ("strict rate control"). Whereas some data indicate that faster rates may be acceptable (lenient rate control), this is not generally recommended. Exceptions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A patient with paroxysmal AF with frequent episodes of fast AF and slow, symptomatic rates when in sinus rhythm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A patient with permanent AF who is asymptomatic with resting rates as fast as 110 beats per minute. However, this group of patients has not been well studied.
        </p>
        <p>
        </p>
        <p>
         We typically start with a beta blocker. (See
         <a class="local">
          'Medications'
         </a>
         above.)
        </p>
        <p>
         In patients with HFpEF (but not HFrEF), we use a nondihydropyridine calcium channel blocker if a beta blocker is not tolerated.
        </p>
        <p>
         We use
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         cautiously in HFpEF, but it can be helpful in combination with a beta blocker to control ventricular response rate, especially in older patients. Other strategies are similar to rate control strategies in patients with AF and HFrEF. (See
         <a class="local">
          'Rate control in heart failure with reduced ejection fraction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2654862152">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies present conflicting data as to whether AF is an independent predictor of mortality in patients with HF [
         <a href="#rid6">
          6-8,56-59
         </a>
         ]. Most were performed several years ago and may not be as generalizable to current patients.
        </p>
        <p>
         However, two more recent studies suggest AF may be associated with increased mortality among patients with HF. A meta-analysis of 16 studies with nearly 54,000 patients showed that among patients with HF, AF was associated with modestly increased mortality (odds ratio of 1.4 among seven randomized trials of HF therapy; 1.15 among nine observational studies) [
         <a href="#rid60">
          60
         </a>
         ]. A registry study of nearly one million patients with HF suggested that new-onset AF was associated with worse mortality than long-standing AF, over a follow-up period of over 13 years [
         <a href="#rid61">
          61
         </a>
         ]. In this analysis, patients who developed new-onset AF had greater mortality than patients with long-standing AF (59 versus 49 percent). Among persons with HF and AF compared with persons with neither condition, the adjusted odds of death was 8.76 (95% CI 8.31–9.23).
        </p>
        <p>
         A post-hoc analysis of a beta blocker trial of nearly 2400 participants with HF showed that new-onset AF (in 190 patients) predicted worse HF-related outcomes [
         <a href="#rid62">
          62
         </a>
         ]. In this study, participants with new-onset AF were at a higher risk of HF mortality (28 versus 23 percent, HR 2.0, 95% CI 1.50-2.67) and had more HF hospitalization days (average of 15 versus 7 days per patient) than those who did not develop AF.
        </p>
        <p class="headingAnchor" id="H1037620342">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">
          "Society guideline links: Atrial fibrillation"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115372.html" rel="external">
          "Society guideline links: Heart failure in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13839780">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16443.html" rel="external">
          "Patient education: Heart failure and atrial fibrillation (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Background and epidemiology
         </strong>
         – Comorbid atrial fibrillation (AF) and heart failure (HF) is common. The prevalence of AF in patients with HF increases from 4 to 50 percent as HF functional class declines. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         AF can impair myocardial atrial and ventricular function, which can both cause and worsen HF. (See
         <a class="local">
          'mechanisms of cardiac dysfunction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute management
         </strong>
         – In all patients, we anticoagulate (irrespective of ejection fraction [EF] or whether a long-term rate or rhythm control management strategy is employed), treat acute HF decompensation with diuretics and vasodilators, and correct potential reversible causes of AF and HF. (See
         <a class="local">
          'Acute decompensation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         In patients with AF and acute HF, we target rate control to &lt;120 beats per minute;
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          amiodarone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         are appropriate agents in this setting. (See
         <a class="local">
          'Acute rate control'
         </a>
         above.)
        </p>
        <p>
         Cardioversion is rarely employed in the setting of AF with acute HF decompensation. (See
         <a class="local">
          'Role of cardioversion'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term management
         </strong>
         –
         <strong>
         </strong>
         For most patients with AF and compensated HF, we suggest rhythm rather than rate control as an initial treatment strategy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Long-term management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A rate control strategy may be preferred in patients with long-standing AF or severe left atrial enlargement, as cardioversion is less likely to be successful or durable in these patients. A rate control strategy may also be reasonable for those unwilling to undergo the burdens of a rhythm control strategy, particularly if they tolerate AF well. (See
         <a class="local">
          'Preference for rhythm over rate control'
         </a>
         above and
         <a class="local">
          'Rhythm control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We employ a stepwise approach, including the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Long-term anticoagulation
         </strong>
         – Patients require anticoagulation prior to, during, and after electrical or pharmacologic cardioversion and catheter ablation (CA). (See
         <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">
          "Atrial fibrillation in adults: Use of oral anticoagulants"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cardioversion
         </strong>
         –
         <strong>
         </strong>
         After acute stabilization,
         <strong>
         </strong>
         for nearly all patients with AF and HF, we suggest electrical cardioversion as initial treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This can be done without an antiarrhythmic medication if this is the first episode of AF, AF is well tolerated, HF is not difficult to manage, and there is no hemodynamically significant mitral regurgitation or left atrial enlargement. (See
         <a class="local">
          'Electrical cardioversion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiarrhythmics
         </strong>
         – For patients who return to persistent AF after electrical cardioversion or fail cardioversion, we suggest
         <a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">
          dofetilide
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Contraindications to dofetilide include QT prolongation, potassium fluctuations, and renal dysfunction.
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         is a reasonable alternative for older individuals and
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         for patients with mild renal dysfunction.
         <em>
         </em>
         (See
         <a class="local">
          'Rhythm control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Catheter ablation
         </strong>
         – For patients with symptomatic AF who have HF without acute decompensation, and failure of antiarrhythmic drug therapy, we suggest CA of AF (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). This recommendation assumes that the patient is a reasonable candidate. (See
         <a class="local">
          'Catheter ablation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Rate control
         </strong>
         – If a rate control strategy is chosen in patients with HF with reduced EF (HFrEF), we recommend beta blockers rather than calcium channel blockers or
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         as initial therapy (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). (See
         <a class="local">
          'Rate control in heart failure with reduced ejection fraction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         We also suggest beta blocker therapy for rate control in patients with HF with preserved EF (HFpEF) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Nondihydropyridine calcium channel blocker therapy is an alternative in patients with HFpEF who cannot tolerate or do not respond to beta blocker therapy.
        </p>
        <p class="bulletIndent2">
         We use a heart rate goal of &lt;85 beats per minute at rest and &lt;110 beats per minute during moderate exercise (the strict approach). If this is not possible, the goal becomes &lt;110 beats per minute at rest (the lenient approach). Lenient rate control goal is used more in patients with HFpEF. (See
         <a class="local">
          'Rate control goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Atrioventricular node ablation with pacing
         </strong>
         – For patients who fail a rate control strategy using medication and are either not candidates for or have failed a rhythm control strategy, atrioventricular node ablation with pacing is an effective therapeutic option. (See
         <a class="local">
          'Atrioventricular node ablation with pacing'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1012.html" rel="external">
          "Atrial fibrillation: Atrioventricular node ablation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – AF is associated with an increased mortality and increased risk of HF progression. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3687778030">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff thank Dr. Alan Cheng for his contributions as an author to prior versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lip GY, Heinzel FR, Gaita F, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016; 18:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:2071.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130:e199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation 2019; 140:e125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gopinathannair R, Chen LY, Chung MK, et al. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol 2021; 14:HAE0000000000000078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson PE, Johnson GR, Dunkman WB, et al. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87:VI102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevenson WG, Stevenson LW, Middlekauff HR, et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol 1996; 28:1458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joglar JA, Acusta AP, Shusterman NH, et al. Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program. Am Heart J 2001; 142:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney P, Kimmel S, DeNofrio D, et al. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am J Cardiol 1999; 83:1544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91:2D.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994; 344:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnstone D, Limacher M, Rousseau M, et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100:2312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995; 333:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yusuf S, Pepine CJ, Garces C, et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicoli CD, O'Neal WT, Levitan EB, et al. Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction. Heart 2022; 108:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cha YM, Redfield MM, Shen WK, Gersh BJ. Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle. Circulation 2004; 109:2839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santhanakrishnan R, Wang N, Larson MG, et al. Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation 2016; 133:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pozzoli M, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998; 32:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69:1570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kieny JR, Sacrez A, Facello A, et al. Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy. Eur Heart J 1992; 13:1290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfield MM, Kay GN, Jenkins LS, et al. Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation. Mayo Clin Proc 2000; 75:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobue Y, Watanabe E, Lip GYH, et al. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF). Heart Vessels 2018; 33:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li A, Li MK, Crowther M, Vazquez SR. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. Thromb Res 2020; 194:240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mar PL, Gopinathannair R, Gengler BE, et al. Drug Interactions Affecting Oral Anticoagulant Use. Circ Arrhythm Electrophysiol 2022; 15:e007956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang SH, Chou IJ, Yeh YH, et al. Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 2017; 318:1250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill K, Sucha E, Rhodes E, et al. Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults. CJC Open 2022; 4:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rillig A, Magnussen C, Ozga AK, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation 2021; 144:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkash R, Wells GA, Rouleau J, et al. Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. Circulation 2022; 145:1693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones DG, Haldar SK, Hussain W, et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 2013; 61:1894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan MN, Jaïs P, Cummings J, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008; 359:1778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter RJ, Berriman TJ, Diab I, et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014; 7:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prabhu S, Taylor AJ, Costello BT, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol 2017; 70:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joy PS, Gopinathannair R, Olshansky B. Effect of Ablation for Atrial Fibrillation on Heart Failure Readmission Rates. Am J Cardiol 2017; 120:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358:2667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suman-Horduna I, Roy D, Frasure-Smith N, et al. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol 2013; 61:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torp-Pedersen C, Møller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med 1999; 341:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 2001; 104:292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998; 98:2574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinfeld MS, Drazner MH, Stevenson WG, Stevenson LW. Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure. J Heart Lung Transplant 2000; 19:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann MH, Hardy S, Archibald D, et al. Sex difference in risk of torsade de pointes with d,l-sotalol. Circulation 1996; 94:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008; 358:2678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccini JP, Hasselblad V, Peterson ED, et al. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol 2009; 54:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 2018; 378:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turagam MK, Garg J, Whang W, et al. Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials. Ann Intern Med 2019; 170:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anselmino M, Matta M, D'Ascenzo F, et al. Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014; 7:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi T, Ohtani T, Mizote I, et al. Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension. J Cardiol 2013; 61:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotecha D, Flather MD, Altman DG, et al. Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 2017; 69:2885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rienstra M, Damman K, Mulder BA, et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasparini M, Regoli F, Galimberti P, et al. Cardiac resynchronization therapy in heart failure patients with atrial fibrillation. Europace 2009; 11 Suppl 5:v82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Androulakis E, Sohrabi C, Briasoulis A, et al. Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107:2920.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crijns HJ, Tjeerdsma G, de Kam PJ, et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J 2000; 21:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47:1997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasywich CA, Whalley GA, Gamble GD, et al. Does rhythm matter? The prognostic importance of atrial fibrillation in heart failure. Heart Lung Circ 2006; 15:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mamas MA, Caldwell JC, Chacko S, et al. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 2009; 11:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziff OJ, Carter PR, McGowan J, et al. The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry. Int J Cardiol 2018; 252:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med 2014; 127:963.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 977 Version 73.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26297713" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682348" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24682347" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30686041" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34129347" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8500233" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8917258" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Improving survival for patients with atrial fibrillation and advanced heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741514" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11526364" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effect of carvedilol on survival and hemodynamics in patients with atrial fibrillation and left ventricular dysfunction: retrospective analysis of the US Carvedilol Heart Failure Trials Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363868" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12670636" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2057035" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3520315" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7914611" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1529944" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10587334" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7539890" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2883575" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1359258" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34031160" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15197156" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26746177" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9669270" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1598871" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1396842" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Increase in radionuclide left ventricular ejection fraction after cardioversion of chronic atrial fibrillation in idiopathic dilated cardiomyopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10943231" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Tachycardia-related cardiomyopathy: a common cause of ventricular dysfunction in patients with atrial fibrillation referred for atrioventricular ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29067492" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33213849" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35622425" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Drug Interactions Affecting Oral Anticoagulant Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28973247" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35386137" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Amiodarone, Verapamil, or Diltiazem Use With Direct Oral Anticoagulants and the Risk of Hemorrhage in Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34328366" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35313733" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23500267" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18946063" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pulmonary-vein isolation for atrial fibrillation in patients with heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24382410" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28855115" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28886855" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effect of Ablation for Atrial Fibrillation on Heart Failure Readmission Rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565859" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Rhythm control versus rate control for atrial fibrillation and heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265334" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10486417" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11457747" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9843465" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10930812" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Early outcome of initiating amiodarone for atrial fibrillation in advanced heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8921798" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Sex difference in risk of torsade de pointes with d,l-sotalol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18565860" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Increased mortality after dronedarone therapy for severe heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19744618" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29385358" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Catheter Ablation for Atrial Fibrillation with Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30583296" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Catheter Ablation of Atrial Fibrillation in Patients With Heart Failure: A Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25262686" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Catheter ablation of atrial fibrillation in patients with left ventricular systolic dysfunction: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23548374" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Switching from carvedilol to bisoprolol ameliorates adverse effects in heart failure patients with dizziness or hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28467883" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24621795" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19861396" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cardiac resynchronization therapy in heart failure patients with atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35053984" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12771006" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10924313" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16697316" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17046323" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Does rhythm matter? The prognostic importance of atrial fibrillation in heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19553398" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29249421" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24931393" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : New-onset atrial fibrillation predicts heart failure progression.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
